TOPLINE Among adults with overweight or obesity, tirzepatide was associated with greater weight reduction and glycemic improvement than semaglutide but was also linked to a higher risk for serious adverse events, according to a meta-analysis of head-to-head studies. METHODOLOGY Incretin-based agents such as tirzepatide and semaglutide have emerged as highly effective options for weight loss…
Read More
Tirzepatide Beats Semaglutide for Weight Loss, Not Safety
